Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- RH +17.1%, SUNW +8.7%, VRNT +7.7%, OLLI +2.4%, UNF +2.2%, HOTR +0.5%
M&A news:
- EXAR +22.2% (to be acquired by MaxLinear (MXL) for $13.00/share in cash)
- CERU +17.2% (Pending merger partner Daré Bioscience discloses 20.7% active stake), .
Other news:
- TNXP +51.9% (will present at The MicroCap Conference on April 4)
- CBIO +30.3% (continued strength following yesterday's 180% move higher)
- SNOA +19.9% (confirms FDA 510(k) clearance for Loyon Skin Descaler)
- VRTX +19% (confirms two Phase 3 Studies of the tezacaftor/ivacaftor combination treatment met primary endpoints with statistically significant improvements in lung function in people with cystic fibrosis)
- SGMO +16% (presentation of new human in vitro and animal model data demonstrating significant reduction of tau mRNA and tau protein expression using the Co's zinc finger protein transcription factor (ZFP-TF)-mediated gene regulation technology)
- DRWI +14.8% (DragonWave's Harmony Enhanced MC backhaul solution was selected by Knoxville Utilities Board )
- IDXG +12.8% (confirms earnings release date for March 29 after the stock market closes)
- ZSAN +9.4% (Amzak Capital Management disclosed increased passive stake to 13.51% (prior 3.61%))
- DRYS +8% (continued strength)
- VIAV +5.1% (AlphaOne Capital Partners' Daniel Niles mention on CNBC FastMoney)
- EGLT +5% (FDA does not object to Egalet's distribution of promotional materials and communications to healthcare professionals regarding the abuse-deterrent properties of ARYMO ER release tablets)
- LITE +2.4% (AlphaOne Capital Partners' Daniel Niles mention on CNBC FastMoney )
- WSM +1% (RH sympathy)
- ACOR +1% (announces results from two studies of CVT-30g)
- INOV +1% (enters into an agreement with Amgen (AMGN) focusedspecifically on rheumatoid arthriti)
Analyst comments:
- CC +3% (upgraded to Buy from Hold at Jefferies)
- EGO +2.8% (upgraded to Buy from Hold at Canaccord Genuity)
- NRG +2.2% (upgraded to Buy from Neutral at Goldman)
- FTNT +2% (upgraded to Outperform at Robert W. Baird)
- MS +1.1% (upgraded to Buy from Hold at Deutsche Bank)
- AMZN +0.5% (initiated with Overweight ratings at Barclays)
- BABA +0.5% (initiated with Overweight ratings at Barclays)